Evidence map›Paper›PMID 24475310›Full record

ArticlePloS one2014

Addition of immunosuppressive treatment to hemoperfusion is associated with improved survival after paraquat poisoning: a nationwide study.

Wen-Pyng Wu, Ming-Nan Lai, Ching-Heng Lin, Yu-Fen Li, Ching-Yuang Lin, Ming-Ju Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wen-Pyng WuGraduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan ; Division of Nephrology, Chang-Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
Ming-Nan LaiDepartment of Statistics, Feng Chia University, Taichung, Taiwan.
Ching-Heng LinDepartment of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Yu-Fen LiInstitute of Biostatistics, China Medical University, Taichung, Taiwan.
Ching-Yuang LinGraduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan ; Clinical Immunology Center, China Medical University Hospital, Taichung, Taiwan.
Ming-Ju WuGraduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan ; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan ; School of Medicine, Chung-Shan Medical University, Taichung, Taiwan ; Graduate Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan ; Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Xitun District, Taichung City, Taiwan.
China Medical University · TWNational Yang Ming Chiao Tung University · TWFeng Chia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraquat poisoning associates very high mortality rate. Early treatment with hemoperfusion is strongly suggested by animal and human studies. Although the survival benefit of additional immunosuppressive treatment (IST) in combination with hemoperfusion is also reported since 1971, the large-scale randomized control trials to confirm the effects of IST is difficult to be executed. Therefore, we designed this nationwide large-scale population-based retrospective cohort study to investigate the outcome of paraquat poisoning with hemoperfusion and the additional effects of IST combined with hemoperfusion. This nationwide retrospective cohort study utilized data retrieved from the National Health Insurance Research Database (NHIRD) of Taiwan. A total of 1811 hospitalized patients with a diagnosis of paraquat poisoning who received hemoperfusion between 1997 and 2009 were enrolled. The mean age of all 1811 study subjects was 47.3 years. 70% was male. The overall survival rate was only 26.4%. Respiratory failure and renal failure were diagnosed in 56.2% and 36% patients. The average frequency of hemoperfusion was twice. IST was added in 42.2% patients. IST significantly increases survival rate (from 24.3% to 29.3%, P<0.001). The combined IST with methylprednisolone, cyclophosphamide and dexamethasone associates with the highest survival rate (48%, P<0.001). Moreover, patients younger than 45 years of age in the IST group had the best survival (41.0% vs. 33.7%, p<0.001). Our results support the use of IST with hemoperfusion for paraquat-poisoned patients. The best survival effect of IST is the combination of methylprednisolone, cyclophosphamide and daily dexamethasone, especially in patients with younger age.

Indexed as

AdultAge FactorsCohort StudiesCyclophosphamideDexamethasoneHemoperfusionHumansImmunosuppression TherapyMaleMethylprednisoloneMiddle AgedParaquatPoisoningProportional Hazards ModelsRetrospective StudiesSurvival RateCyclophosphamideDexamethasoneMethylprednisoloneParaquat

Identifiers

PMID24475310
PMCPMC3903773
OpenAlexW2010082093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.